ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Justin Chakma Sells 25,000 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Justin Chakma sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $14.39, for a total transaction of $359,750.00. Following the completion of the sale, the insider now owns 136,380 shares in the company, valued at $1,962,508.20. This represents a 15.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Justin Chakma also recently made the following trade(s):

• On Monday, November 25th, Justin Chakma sold 32,814 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $14.00, for a total transaction of $459,396.00.

ARS Pharmaceuticals Trading Up 1.1 %

Shares of SPRY stock opened at $14.53 on Thursday. ARS Pharmaceuticals, Inc. has a 1-year low of $4.65 and a 1-year high of $18.51. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -28.49 and a beta of 0.90. The stock has a 50-day moving average of $14.82 and a 200-day moving average of $11.97.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. nVerses Capital LLC bought a new stake in ARS Pharmaceuticals during the third quarter valued at $30,000. Russell Investments Group Ltd. bought a new stake in shares of ARS Pharmaceuticals during the 1st quarter valued at about $60,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ARS Pharmaceuticals by 151.7% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after purchasing an additional 4,472 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in ARS Pharmaceuticals during the second quarter worth approximately $87,000. Finally, Quarry LP bought a new stake in ARS Pharmaceuticals in the third quarter worth approximately $174,000. Institutional investors own 68.16% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on SPRY shares. William Blair upgraded ARS Pharmaceuticals to a “strong-buy” rating in a research report on Friday, August 30th. Leerink Partners boosted their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their price objective for the company from $18.00 to $22.00 in a report on Tuesday, August 13th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $24.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.